GI Surgery – Stomach and Duodenum
ERAS Guidelines for perioperative care in elective abdominal and pelvic surgery at primary and secondary hospitals in low–middle-income countries.
1 Jun, 2022 | 12:08h | UTCRelated:
Complete List of Enhanced Recovery After Surgery (ERAS) Society Guidelines
Long-term impact of Helicobacter pylori eradication therapy on gastric cancer incidence and mortality in healthy infected individuals: A meta-analysis beyond 10 years of follow-up.
31 May, 2022 | 11:47h | UTC
Commentary from the author on Twitter (thread – click for more)
Our latest research letter is published in @AGA_Gastrohttps://t.co/MCJBLgwh1F
It was inspired by two recent long-term follow-ups of RCTs of population screening and treatment for H. pylori to prevent gastric cancer published in the journal.
— Alexander Ford (@alex_ford12399) May 20, 2022
The current and future incidence and mortality of gastric cancer in 185 countries, 2020–40: A population-based modelling study.
19 May, 2022 | 10:19h | UTC
NCCN Guideline: Gastric Cancer.
29 Apr, 2022 | 08:05h | UTC
A comprehensive and comparative review of global gastric cancer treatment guidelines.
26 Apr, 2022 | 07:39h | UTC
Prevention and management of postoperative ileus: a review of current practice.
12 Apr, 2022 | 08:20h | UTCPrevention and Management of Postoperative Ileus: A Review of Current Practice – Cureus
RCT: Laparoscopic sentinel node navigation surgery for stomach preservation in patients with early gastric cancer.
8 Apr, 2022 | 09:59h | UTC
Commentary on Twitter
In a phase III noninferiority trial of laparoscopic sentinel node navigation surgery vs standard gastrectomy for gastric cancer, 3-year DFS was 91.8% vs 95.5%, but with fewer complications, better physical function, improved nutrition & similar DSS/OS: https://t.co/A7Z8tejiIA
— NatureRevClinOncol (@NatRevClinOncol) March 30, 2022
Case-cohort study: The relative and attributable risks of cardia and non-cardia gastric cancer associated with Helicobacter pylori infection in China.
7 Apr, 2022 | 08:22h | UTCCommentary: Helicobacter pylori infection and risk of gastric cancer – The Lancet Public Health
Review: Surgical management of gastric cancer.
25 Mar, 2022 | 08:48h | UTCSurgical Management of Gastric Cancer: A Review – JAMA Surgery (free for a limited period)
Multidisciplinary evidence-based recommendations for the management of malignant bowel obstruction in advanced cancer.
24 Mar, 2022 | 08:45h | UTC
RCT: Effect of early vs. late supplemental parenteral nutrition in patients undergoing abdominal surgery.
17 Mar, 2022 | 08:43h | UTCInvited Commentary: Early Postoperative Supplementary Parenteral Nutrition – JAMA Surgery
Author Interview: Supplemental Parenteral Nutrition in Patients Undergoing Abdominal Surgery
Commentary on Twitter
Randomized clinical trial found supplemental parenteral nutrition in combination with enteral nutrition could significantly reduce the incidence of nosocomial infections in patients undergoing abdominal surgery. https://t.co/Agbf9TKPfX
— JAMA Surgery (@JAMASurgery) March 16, 2022
Systematic Review: Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding.
6 Mar, 2022 | 23:41h | UTC
ESGE Guideline: Endoscopic management of subepithelial lesions, including neuroendocrine neoplasms.
21 Feb, 2022 | 08:49h | UTC
M-A: Laparoscopic versus open distal gastrectomy for gastric cancer.
3 Feb, 2022 | 08:30h | UTC
M-A: Clinical and endoscopic characteristics associated with post-endoscopy upper gastrointestinal cancers.
28 Jan, 2022 | 08:08h | UTCClinical and Endoscopic Characteristics Associated with Post-Endoscopy Upper Gastrointestinal Cancers: a Systematic Review and Meta-analysis – Gastroenterology (link to abstract – $ for full-text)
Review: Diagnostic evaluation of gastric motor and sensory disorders.
21 Jan, 2022 | 09:42h | UTCDiagnostic Evaluation of Gastric Motor and Sensory Disorders – American Journal of Gastroenterology
ESGE Guideline: Endoscopic management of enteral tubes in adult patients.
3 Dec, 2021 | 10:02h | UTCEndoscopic management of enteral tubes in adult patients: European Society of Gastrointestinal Endoscopy (ESGE) Guideline – Endoscopy
Part 1: Definitions and indications.
Part 2: Peri- and post-procedural management.
M-A (mostly observational studies): Comparison of gastrojejunostomy to endoscopic stenting for gastric outlet obstruction.
30 Nov, 2021 | 10:08h | UTC
Guideline | Endoscopic tissue sampling – Part 1: Upper gastrointestinal and hepatopancreatobiliary tracts.
26 Nov, 2021 | 09:41h | UTC
Clinical Guideline Highlights for the Hospitalist: Management of Upper Gastrointestinal and Ulcer Bleeding.
21 Nov, 2021 | 22:44h | UTCClinical Guideline Highlights for the Hospitalist: Management of Upper Gastrointestinal and Ulcer Bleeding – Journal of Hospital Medicine (free for a limited period)
AGA Clinical Practice Update on Endoscopic Management of Perforations in Gastrointestinal Tract.
27 Oct, 2021 | 01:35h | UTC
RCT: Laparoscopic vs. open distal gastrectomy for locally advanced gastric cancer.
26 Oct, 2021 | 01:40h | UTCLaparoscopic vs Open Distal Gastrectomy for Locally Advanced Gastric Cancer: Five-Year Outcomes From the CLASS-01 Randomized Clinical Trial – JAMA Surgery (free for a limited period)
Commentary on Twitter
It is not clear whether laparoscopic (LDG) and open distal gastrectomy (ODG) produce similar long-term outcomes in advanced #gastriccancer. CLASS-01 trial firstly shows LDG results in similar 5-year OS compared to ODG in advanced gastric cancer https://t.co/uUBcLFeqsY
— JAMA Surgery (@JAMASurgery) October 20, 2021
Roux‐en‐Y versus Billroth‐I reconstruction after distal gastrectomy for gastric cancer.
19 Sep, 2021 | 23:24h | UTC
Global Incidence and Mortality of Gastric Cancer, 1980-2018
13 Aug, 2021 | 08:45h | UTCGlobal Incidence and Mortality of Gastric Cancer, 1980-2018 – JAMA Network Open
Ranitidine absolved? FDA study finds Ranitidine does not convert to carcinogen NDMA, regardless of diet.
12 Jul, 2021 | 01:36h | UTCEditorial: Ranitidine and Risk of N-Nitrosodimethylamine (NDMA) Formation
Commentary: Ranitidine: FDA finds no evidence of elevated NDMA, regardless of diet
Commentaries on Twitter
Despite ranitidine (zantac) being pulled from market last year, a new study from the FDA did not find evidence that it increases concentrations of the carcinogenic metabolite people were worried about (i.e., it's probably safe). From @JAMA_current https://t.co/AdRic2GdXS
— Zack Williams (@QuantPsychiatry) June 28, 2021
In this crossover, randomized clinical trial, oral ranitidine did not significantly increase 24-hour urinary excretion of NDMA when administered with a noncured-meats diet or a cured-meats diet. https://t.co/EszRvfJOFJ
— JAMA (@JAMA_current) June 28, 2021